The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to Section 130a (8) of the German Social Code (SGB) for medicinal products for the combination of fusion acid/betamethasone (WHO ATC code: D07CC01) within the framework of an open-house model. All interested and suitable pharmaceutical companies are offered to conclude a discount agreement in accordance with Section 130a (8) SGB V, subject to uniform conditions and a uniform access procedure. There is no exclusivity. The purchase volume is unknown at the time of conclusion of the agreement and depends in particular on the demand of the insured persons, the development of the number of insured persons, the prescription behaviour of contract doctors and the distribution and stockpiling behaviour of public pharmacies. The client does not guarantee minimum order quantities.

For further information see point II.2.4) of the announcement.

The agreement can be concluded at any time and on the same terms. Individual contract negotiations are not carried out.

Interested pharmaceutical companies may request the participation documents (discount agreement, non-exclusion self-declaration, declaration of exclusion, declaration of conformity) via the e-mail address referred to in I.1). Agreements under this model will be concluded for the period from 16 June 2021 to 31 July 2023. Interested parties shall submit the completed and signed participation documents (self-declaration of non-exclusion grounds, 2-fold rebate agreement, declaration of conformity) to the body referred to in point I.1) for the first time by 15.6.2021, and then by 15 months thereafter. It all depends on access to the AOK Plus. If the 15th of a month falls on a public holiday on Saturdays, Sundays or nationwide, the next working day shall take the place of such a day. In the event of subsequent receipt (after 15.6.2021 or 15 of each month), the participation documents submitted shall be taken into account on the 15th of the following month.

The discount agreement shall enter into force on 1 August 2021 when both parties are signed by 31 July 2021. If the date of signature of AOK Plus is later than 31 July 2021, this discount agreement will enter into force once the AOK Plus has signed the discount agreement upon receipt of the complete documentation signed by the pharmaceutical company. Signing shall take place by the end of the month in which the participation documents must be received by AOK Plus. Organisationally, an advance of approximately half a month on the part of AOK Plus is necessary to report the discount agreement. The initial labelling of the rebate medicines in the pharmacy software takes place from the second month following the time limit for receipt of the participation documents. This date may vary in the event of changes or revisions of the deadlines for reporting in the nationwide AOK contract registration portal datraBatt. A discount agreement is concluded with all pharmaceutical entrepreneurs who meet the eligibility requirements and confirm this by signing the requested documents. The contract ends no later than July 31, 2023, regardless of the date of conclusion of the contract. AOK Plus reserves the right to terminate the open-house procedure prematurely, especially if exclusive discount agreements are concluded. In this case, the contracts already concluded shall terminate in accordance with the contractual provisions. According to the experience of AOK Plus, exclusive discount agreements shall normally enter into force 8 to 12 months after the publication of the relevant notice of invitation to tender in the Supplement to the Official Journal of the European Union. The future contracting parties in the open-house model are requested to inform themselves regularly in the Supplement to the Official Journal of the European Union.